Quantcast

The Consumer Justice Foundation Alerts Public to FDA Announcement 90 More Days Are Needed for an Approval Decision on Topiramate-Containing Diet Medication Qnexa

April 12, 2012

The Consumer Justice Foundation, a for-profit corporation that is staffed by a team of professional consumer advocates whose mission is to provide consumers with information regarding the potential dangers of certain prescription medications via free online informational resources, hereby alerts the public of an FDA announcement that its decision regarding whether or not to approve the topiramate-containing obesity medication Qnexa will not be made on April 17. Instead, the agency will make its approval decision on July 17, 2012. Information regarding topiramate and its brand name drug Topamax can be found at http://www.topamaxbirthinjury.com.

(PRWEB) April 12, 2012

The Consumer Justice Foundation, a for-profit corporation whose staff is comprised of professional consumer advocates who provide free online informational resources with regards to the potential dangers of certain prescription medications, hereby alerts the public of an FDA announcement that the agency will require an additional 90 days to decide whether or not the obesity drug known as Qnexa will be approved for use in the United States. One of the active ingredients in Qnexa is topiramate, which is marketed and sold as Topamax.

The FDA stated that it would require this additional 90 days because it desires more time to review the safety strategy for the drug, as there have been questions raised during the approval process regarding potential dangers relating to its use. Specifically, these dangers relate to the presence of topiramate in the drug´s formula, as Topamax side effects have been reported to include the tendency for women who have used Topamax during pregnancy to have children who were born with clefts. Topamax is an anticonvulsant medication that is manufactured by Johnson & Johnson. Qnexa is manufactured by Vivus, Inc., and the other active ingredient in this obesity medication is phentermine, which is an appetite suppressant.

About the Consumer Justice Foundation

The Consumer Justice Foundation, whose Web site can be found at http://www.consumerjusticefoundation.com, is a for-profit organization that serves two purposes for consumers: (1) to provide educational information regarding the policies and procedures of large corporations and how they affect the average consumer; and (2) to provide news updates and resources that continue to update consumers regarding developments taken by corporations that include pharmaceutical drug companies, auto manufacturers and insurance companies so that consumers who have been harmed can use these informational resources to connect to an experienced professional who can help them. The team at the Consumer Justice Foundation is staffed by experienced and passionate consumer advocates whose mission is to raise the awareness of issues that could pose a risk of harm to those who may not otherwise be aware of the dangers they face.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/4/prweb9394857.htm


Source: prweb



comments powered by Disqus